Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 5/17/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Gary Rabin?

Gary H. Rabin

Chief Executive Officer

Australian Capital Territory

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Australian Capital Territory

Background Information

Employment History

Chief Executive Officer

Ocata Therapeutics, Inc.


Chief Executive Officer

Advanced Cell Technology , Inc.


Managing Partner

GR Advisors, LLC


Managing Director, Co-Head and Founder

The Industry Group


Web References(172 Total References)


ISPE Boston News Viewing News - Industry News in Brief

www.ispeboston.org [cached]

"We expect that a number of our embryonic stem cell lines will be approved for funding in the coming months," ACT CEO Gary Rabin said in a statement.
ACT has Phase I trials underway for stem cell treatments it has developed for Stargardt's Macular Dystrophy and Dry AMD, which lead to blindness. Rabin wrote in his blog that "myths and misunderstanding" still permeate the stem cell research discussion, though 12 years have passed since the first human embryonic stem cell (hESC) line was derived. He noted that ACT derives hESCs through a patented technique that removes a single cell from an embryo without damaging or destroying it, which eliminates many of the ethical and religious arguments against embryonic stem cell research.


www.genengnews.com

Commenting on the findings, ACT chairman and CEO Gary Rabin said, "In addition, we have observed persisting engraftment of the transplanted RPE cells in our more recent SMD and dry AMD patients.


To See Again (Advanced Cell Technology, Inc) - Stock Pick 101

stockpick101.com [cached]

According to ACTC, the stem cells for that study were derived from an embryo created in a fertility clinic by a couple that chose not to use it to create a pregnancy, said Gary Rabin, chief executive officer of Advanced Cell Technology, who said the couple donated the embryo to the company.


ir.advancedcell.com

However, as of October 1, 2013, we determined that the roles should be separated and Mr. Heffernan became the Chairman of the Board of Directors and Mr. Rabin became Chief Executive Officer and a member of the Board of Directors.
Subsequently, on January 21, 2014, the Board and Mr. Rabin mutually agreed that he would cease serving in his roles as Chief Executive Officer and as a director of the Company, effective immediately. Gary Rabin, a director and Chief Executive Officer, filed a Form 4 late with respect to one transaction executed in January 2013. This section describes the compensation program for the following executive officers, each of which are considered our "Named Executive Officers" for 2013 under applicable SEC rules: Gary Rabin (Chief Executive Officer through January 21, 2014), Robert P. Lanza, M.D. (Chief Scientific Officer) and Edward Myles (Interim President, Chief Financial Officer and Executive Vice President of Corporate Development). Based on its analysis of peer group compensation and practices, Radford recommended, and the Compensation Committee approved, that 2013 base salaries of Mr. Rabin and Dr. Lanza increase by 5% from 2012, which represented the required increase per their respective employment agreements, which were in place at that time. Gary Rabin After considering Radford's report and recommendations, and based on discussions with both Radford and Mr. Rabin, the Compensation Committee established a 2013 cash bonus incentive arrangement for the Named Executive Officers. The target bonus opportunity was 60% of annual base salary for Mr. Rabin, 40% of annual base salary for Dr. Lanza and 35% of annual base salary for Mr. Myles. Gary Rabin (2) On January 21, 2014, the Board and Mr. Rabin mutually agreed that he would cease serving in his roles as Chief Executive Officer and as a director of the Company, effective immediately. In addition to serving as Chief Executive Officer during fiscal year 2013, Mr. Rabin served as Principal Financial Officer through May 2013 and as Chairman of our Board of Directors through September 2013. Employment Agreement with Gary Rabin Effective July 1, 2011, the Company entered into an amended and restated employment agreement with Gary H. Rabin (the "Rabin Agreement"). Pursuant to the Rabin Agreement, the parties agreed as follows: Mr. Rabin would serve as the Company's chief executive officer and chief financial officer for a term commencing on July 1, 2011 until December 31, 2013 (subject to earlier termination as provided therein). The Company would pay Mr. Rabin a base salary of $500,000 per year, through December 31, 2011, which amount shall increase at the end of each full year of the Rabin Agreement, by an amount determined by the board, but by not less than 5% per year. The Company agreed to pay Mr. Rabin a retention bonus of $41,667 within 10 days of execution of the Rabin Agreement. The retention bonus was paid on August 5, 2011. The Company would pay Mr. Rabin a performance bonus in amount (not less than $100,000 per year) to be determined by the Compensation Committee of the Board of Directors. The Company agreed to issue to Mr. Rabin, upon execution of the Rabin Agreement, (i) 10,000,000 shares of restricted common stock, (ii) an option to purchase 10,000,000 shares of common stock with an exercise price equal to fair market value on the date of grant, (iii) an option to purchase 5,000,000 shares of common stock with an exercise price of $0.30, and (iv) an option to purchase 5,000,000 shares of common stock with an exercise price of $0.45. The options will vest, and the shares will no longer be subject to the Company's right to repurchase for aggregate consideration of $1.00, in equal installments on the last day of each calendar quarter commencing on July 1, 2011 and ending on December 31, 2013. If Mr. Rabin's employment under the Rabin Agreement were to be terminated by the Company without cause (as defined therein), or if Mr. Rabin resigns for good reason (as defined therein), the Company would pay Mr. Rabin (in addition to unpaid base salary, performance bonus and incentive bonus to the date of termination), a lump sum equal to the aggregate installments of base salary in effect on the date of termination and otherwise payable in respect of the period commencing on the date immediately subsequent to the date of termination and ending on the earlier to occur of the first anniversary of such date and December 31, 2013; provided, that, Mr. Rabin execute a standard general release within 60 days of termination. On January 21, 2014, the Board and Mr. Rabin mutually agreed that he would cease serving in his roles as Chief Executive Officer and as a director of the Company, effective immediately. Gary Rabin(1)(2)(3) The targets were based on a percentage of annual base salary and this was 60% for Mr. Rabin, 40% of salary for Dr. Lanza and 35% for Mr. Myles. For Mr. Rabin the maximum bonus could not exceed 125% of the target. (2) In accordance with Mr. Rabin's employment agreement, he is normally entitled to no less than $100,000 per year for any performance-based bonus, however he did not renew his agreement which expired December 31, 2013 and left the Company in January 2014. (3) Pursuant to Mr. Rabin's employment agreement, Mr. Rabin was also eligible to earn a fiscal 2013 incentive-based bonus based on the trading price of the Company's common stock as discussed above under "Employment Agreements. The maximum amount Mr. Rabin was eligible to receive was $1,000,000. Gary Rabin These options held by Mr. Rabin vested in full as of July 1, 2011. (2) These options held by Mr. Rabin vested in equal installments on the last day of each calendar quarter commencing on July 1, 2011 and ending December 31, 2013. Gary Rabin Pursuant to the terms of the Rabin Agreement, if Mr. Rabin had been terminated without Cause or had resigned for Good Reason on December 31, 2013, subject to Mr. Rabin executing a general release of claims against the Company, Mr. Rabin would have been entitled to: (i) within 60 days of December 31, 2013, a lump sum payment of $551,250 (equal to his annual base salary then in effect), and (ii) reimbursement to Mr. Rabin on a month-to-month basis of an amount equivalent to Mr. Rabin's and Mr. Rabin's spouse and dependent's COBRA payments for up to 18 months following the date of termination if Mr. Rabin were to properly elective COBRA coverage, or for the maximum COBRA term allowable by then applicable law for coverage of Mr. Rabin, and his spouse and dependents, for an estimated $28,000 in reimbursements over 18 months, and (iii) full vesting of the stock options and restricted stock incentive awards granted under the Rabin Agreement. The accelerated vesting of stock options and restricted stock would have had no impact at December 31, 2013 as all of Mr. Rabin's stock options and restricted stock were fully vested at that date. Directors who are also one of our employees, such as Mr. Rabin, do not and will not receive any compensation for their services as our directors while they are also serving as an employee. Directors have been and will continue to be reimbursed for travel and other expenses directly related to activities as directors. The foregoing compensation structure for the non-employee directors was established and approved by the Compensation Committee and unanimously ratified by the full Board of Directors in October 2012. Gary Rabin Amended and Restated Employment Agreement dated July 1, 2011 by and between the Registrant and Gary H. Rabin* Separation Agreement, dated as of January 21, 2014 by and between the Registrant and Gary Rabin.


CompanyNews

www.ceocast.com [cached]

"This settlement ends the cost and uncertainty associated with this litigation and resolves all of the litigation relating to the debentures, which have represented an ongoing cost and distraction for both management and our shareholders," said Gary Rabin, chairman and CEO of ACT.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory